Galapagos NV (GXE.DE)
- Previous Close
44.47 - Open
44.18 - Bid --
- Ask --
- Day's Range
44.18 - 44.47 - 52 Week Range
41.70 - 66.40 - Volume
1 - Avg. Volume
62 - Market Cap (intraday)
2.928B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-1.92 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
www.glpg.com1,123
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: GXE.DE
Performance Overview: GXE.DE
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GXE.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GXE.DE
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
88.31%
Return on Assets (ttm)
-1.11%
Return on Equity (ttm)
-0.15%
Revenue (ttm)
239.72M
Net Income Avi to Common (ttm)
-3.99M
Diluted EPS (ttm)
-1.92
Balance Sheet and Cash Flow
Total Cash (mrq)
3.68B
Total Debt/Equity (mrq)
0.34%
Levered Free Cash Flow (ttm)
-124.2M
Company Insights: GXE.DE
GXE.DE does not have Company Insights